Product information and disease description Product description Product information

Average sales price and wholesale acquisition cost

3 evidence topics · 4 sources

Average sales price and wholesale acquisition cost of tovecimig

Not applicable.

Regulatory and commercial status bearing on the absence of a published price for tovecimig

“Q3 26: Meet with FDA Q4 26: Submit BLA” (opens the source at this quote in a new tab)
“potential approval in 2H 2027” (opens the source at this quote in a new tab)
“Expected FDA meeting in Q3 2026 BLA filing initiating in late 2026 2027 potential approval and launch” (opens the source at this quote in a new tab)

“We expect feedback from the FDA in the third quarter regarding the COMPANION-002 Phase 2/3 data, prior to a potential BLA filing later this year.” (opens the source at this quote in a new tab)

Average sales price of paclitaxel, the chemotherapy given with tovecimig in COMPANION-002

“The drug costs were collected from the Centers for Medicare & Medicaid Services (CMS) and the average sales price (ASP) that the manufacturer reported was adopted” (opens the source at this quote in a new tab)
“All costs prior to 2022 have been inflated to 2022 US dollars (USD) using the Consumer Price Index” (opens the source at this quote in a new tab)

Model cost input	Baseline value, USD
Paclitaxel, per 1 mg	“0.115”
Administration of intravenous infusion, first hour	“140.16”
Administration of intravenous infusion, additional hour	“29.76”

Average monthly United States price of orally available kinase inhibitors used in cholangiocarcinoma

“The cost of drugs was obtained from www.pharmacychecker.com using the FDA label to determine the dosage and number of tablets required per day. This methodology excludes any private or governmental insurance coverage, which would cover the entire cost or more likely a fraction of the stated price.” (opens the source at this quote in a new tab)
“The average monthly cost for the treatment of neoplastic diseases was $17,900 with a price of $44,000 for futibatinib (used to treat cholangiocarcinomas with FGFR2 fusions) and minimum of $5100 for binimetinib (melanoma).” (opens the source at this quote in a new tab)
“We retrieved drug prices in November 2023 from www.pharmacychecker.com for the average patient living in the state of North Carolina (ZIP code 28791). These values represent the retail price of a drug at the pharmacy as determined by negotiations between pharmacies and insurers and reflect both wholesale and retail markups.” (opens the source at this quote in a new tab)
“Results from clinical trials do not favor one drug over the other [83]; the difference in pricing is thus unrelated to clinical efficacy.” (opens the source at this quote in a new tab)
“Infigratinib had also been approved for the treatment of this uncommon disorder, but the distribution of this FGFR inhibitor has been discontinued in the United States [84].” (opens the source at this quote in a new tab)